证券代码：688075 证券简称：安旭生物 公告编号：2025-004 杭州安旭生物科技股份有限公司 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●每股分配比例：每 10 股派发现金红利 8 元（含税），不进行资本公积转 增股本，不送红股。 本次利润分配符合相关法律法规及公司章程的规定，不触及《科创板股票上 市规则》第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警示的情形， 相关数据及指标如下表： ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生 变动的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整 情况。 ●公司未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 （以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能 被实施其他风险警示的情形。 一、利润分配预案内容 （一）利润分配预案的具体内容 经中审 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-010 杭州安旭生物科技股份有限公司 关于作废 2024 年限制性股票激励计划 部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开的第二届董事会第十七次会议、第二届监事会第十五次会议，审议通过了 《关于作废 2024 年限制性股票激励计划部分限制性股票的议案》。根据《上市 公司股权激励管理办法》（以下简称"《管理办法》"）等法律法规、规范性文 件及《杭州安旭生物科技股份有限公司 2024 年限制性股票激励计划（草案）》 （以下简称"《激励计划（草案）》"）《杭州安旭生物科技股份有限公司 2024 年限制性股票激励计划实施考核管理办法》（以下简称"《考核管理办法》"） 的有关规定及公司 2024 年第二次临时股东大会的授权，公司董事会同意作废公 司 2024 年限制性股票激励计划（以下简称"本次激励计划"）部分限制性股票 合计 47.80 万股。现将有关事项 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 115,296,526.87, a decrease of 10.9% compared to CNY 129,406,701.97 in the same period last year[4]. - Net profit attributable to shareholders decreased by 51.52% to CNY 34,029,618.77 from CNY 70,190,798.47 year-on-year[4]. - The net profit after deducting non-recurring gains and losses increased by 15.95% to CNY 22,760,297.27 compared to CNY 19,629,646.53 in the previous year[4]. - Net profit for Q1 2025 was CNY 34,227,418.43, down 51.3% from CNY 70,334,720.12 in Q1 2024[19]. - Earnings per share for Q1 2025 was CNY 0.27, compared to CNY 0.55 in Q1 2024[20]. - The company reported a decrease in comprehensive income to CNY 32,331,616.02 in Q1 2025 from CNY 70,370,450.36 in Q1 2024[20]. Cash Flow - The net cash flow from operating activities was negative at CNY -11,098,782.01, compared to a positive CNY 1,008,618.28 in the same period last year[4]. - Net cash flow from operating activities was -$11.1 million, a decrease from $1.0 million in the previous period[23]. - Cash paid for operating activities totaled $138.6 million, compared to $166.1 million last year[23]. - Cash received from sales in Q1 2025 was CNY 103,961,347.43, a decrease from CNY 110,735,727.41 in Q1 2024[22]. - The company reported a net increase in cash and cash equivalents of -$31.8 million, compared to an increase of $321.7 million last year[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,844,995,156.61, reflecting a 1.31% increase from CNY 5,769,310,895.27 at the end of the previous year[5]. - Current assets totaled RMB 4,847,904,481.23, compared to RMB 4,769,982,927.28 at the end of 2024, reflecting a growth of approximately 1.6%[13]. - Total liabilities reached RMB 612,876,253.81, compared to RMB 569,523,608.49 at the end of 2024, marking an increase of about 7.6%[14]. - The company's non-current assets totaled RMB 997,090,675.38, slightly down from RMB 999,327,967.99[14]. - The company's total equity attributable to shareholders was CNY 5,235,733,004.95, reflecting a slight increase from CNY 5,203,599,188.59[15]. Research and Development - Research and development expenses totaled CNY 25,058,704.57, representing an increase of 26.3% from CNY 19,840,217.39 year-on-year[4]. - Research and development expenses rose to CNY 25,058,704.57 in Q1 2025, an increase of 26.5% from CNY 19,840,217.39 in Q1 2024[19]. Non-Recurring Items - The company reported non-recurring gains of CNY 11,269,321.50 after tax, primarily due to government subsidies and other non-operating income[7]. - Other income decreased significantly to CNY 1,725,120.33 in Q1 2025 from CNY 13,159,386.79 in Q1 2024[19]. Inventory and Receivables - The company reported a significant increase in inventory, which stood at RMB 143,539,795.97, compared to RMB 147,167,029.08 previously[13]. - Accounts receivable increased to RMB 283,512,930.50, up from RMB 203,690,596.91, representing a significant rise of approximately 39.2%[13]. Other Information - The total number of ordinary shareholders at the end of the reporting period was 5,935[9]. - The company has not disclosed any new product launches or technological advancements during this reporting period[12]. - There are no significant mergers or acquisitions reported in the current financial period[12].

Financial Performance - The company's revenue for 2024 reached RMB 540,698,462.10, representing a 7.42% increase compared to RMB 503,357,076.78 in 2023[20]. - The net profit attributable to shareholders for 2024 was RMB 192,295,303.31, a significant increase of 35.85% from RMB 141,553,680.39 in 2023[20]. - The net cash flow from operating activities improved to RMB 75,093,227.27 in 2024, recovering from a negative cash flow of RMB -623,082,613.12 in 2023[20]. - The total assets as of the end of 2024 were RMB 5,769,310,895.27, a slight decrease of 0.35% from RMB 5,789,539,225.57 in 2023[20]. - The basic earnings per share for 2024 increased to RMB 1.51, up 36.04% from RMB 1.11 in 2023[21]. - The diluted earnings per share also rose to RMB 1.51, reflecting the same growth rate of 36.04% compared to 2023[21]. - The net profit after deducting non-recurring gains and losses decreased to RMB 37,897,947.37 in 2024, down 27.6% from RMB 52,345,318.72 in 2023[20]. - The gross profit margin decreased by 3.15 percentage points to 39.10% due to rising costs[111]. - The company achieved a revenue of 540.70 million RMB, representing a year-on-year growth of 7.42%[108]. - The net profit attributable to the parent company was 192.30 million RMB, an increase of 35.85% compared to the previous year[108]. Dividend Policy - The company plans to distribute a cash dividend of 8 CNY per 10 shares, totaling approximately 101.67 million CNY for the year, which represents 79.30% of the net profit attributable to shareholders[4]. - The total cash dividend for the year, including interim distributions, amounts to 152.50 million CNY[4]. - The company has a cash dividend policy that allows for profit distribution in cash, stock, or a combination of both, ensuring it does not exceed distributable profits[177]. - The company plans to distribute cash dividends amounting to CNY 101,666,244.00, which represents 52.87% of the net profit attributable to ordinary shareholders in the consolidated financial statements[184]. - The cumulative cash dividend amount over the last three accounting years is CNY 657,199,648.00, with an average net profit of CNY 1,126,174,097.84, resulting in a cash dividend ratio of 58.36%[187]. Research and Development - The company invested 18.69% of its operating revenue in R&D, a decrease of 2.22% compared to the previous year[22]. - The cumulative investment in R&D projects reached ¥578,427,519.68, indicating a strong commitment to innovation and development[87]. - The company has developed 10 new POCT platforms, enhancing its product offerings in the clinical testing market[86]. - The R&D investment as a percentage of operating revenue decreased by 2.22% compared to the previous year, indicating a shift in resource allocation[85]. - The company is actively pursuing new technologies and products, with several projects in various stages of development aimed at enhancing diagnostic capabilities[86]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings in the medical device sector[12]. - The company aims to become a leader in the POCT industry, emphasizing its commitment to providing excellent products and services for human health[32]. - The company is exploring growth potential in pet health management, family health management, and medical laboratory sectors[32]. - The company is focusing on expanding its market presence internationally, with significant certifications obtained in Canada (115) and Australia (9)[84]. - The company is committed to developing eight major product series, particularly in drug testing, with a focus on product iteration and providing better services to ensure stable business growth[144]. Compliance and Governance - The company has not reported any significant governance issues that would affect the accuracy of the annual report[6]. - The company has implemented measures to enhance compliance with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange listing rules[161]. - The internal control audit report issued by Zhonghuan Accounting Firm confirmed that the company maintained effective financial reporting internal controls as of December 31, 2024[200]. - The independent directors supervise the execution of the company's compensation system and provide review opinions on senior management's compensation[198]. - The company aims to enhance its operational compliance and governance standards to promote sustainable development[161]. Innovation and Technology - The company has established nine major technology platforms in the field of precision medical diagnostics, covering eight areas including drug testing, infectious disease testing, and chronic disease testing[34]. - The company is focusing on technology innovation and global ecological chain layout to drive high-quality development[32]. - The company is actively pursuing innovation in core technologies, with platforms for immunochromatography, dry chemistry, and liquid biochips under development[69]. - The company has developed a dry biochemical technology platform that enhances product performance through enzyme catalysis, membrane immobilization, and multi-detection technology, establishing a competitive advantage in chronic disease detection[71]. - The molecular diagnostics segment is the fastest-growing part of the in vitro diagnostics market, focusing on high-throughput and timely technologies[65]. Risks and Challenges - The company has disclosed potential risks that may adversely affect its operations in the management discussion section[3]. - The company faces risks from intensified market competition and potential declines in market share if it fails to maintain its advantages in R&D and product offerings[98]. - The company is at risk of quality control issues due to the complexity of managing multiple stages in the production and supply chain[100]. - The company faced potential risks from stricter regulations under the new EU IVDR, which could impact its manufacturing capabilities[104]. - The company is exposed to risks from currency fluctuations and international market conditions, as over 90% of its main business income comes from overseas sales[101]. Leadership and Management - The company has maintained a stable leadership structure with no changes in shareholdings among key executives during the reporting period[152]. - The overall compensation structure for executives reflects the company's commitment to aligning performance with shareholder interests[153]. - The management team has undergone changes, with new appointments aimed at strengthening operational efficiency[156]. - The company has established a performance evaluation mechanism for senior management, with annual performance bonuses proposed and approved by the board[198]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 499.94 million[160].

杭州安旭生物科技股份有限公司 募集资金年度存放与实际使用情况 的鉴证报告 众环专字(2025) 0300063号 目 录 起始页码 鉴证报告 募集资金专项报告 关于募集资金年度存放与实际使用情况的专项报告 ] 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" 报告编码: 【 2 5 6 6 0 7 . 0 4 4 5 1 3 2 3 2 2 2 2 2 2 2 2 杭州安旭生物科技股份有限公司 度存放与实际使用情况的鉴证报告 众环专字(2025)0300063 号 杭州安旭生物科技股份有限公司全体股东: 我们接受委托,对后附的杭州安旭生物科技股份有限公司(以下简称"安旭生物公司") 截至 2024 年 12 月 31 日止的《董事会关于公司募集资金年度存放与实际使用情况的专项报 告》进行了鉴证工作。 按照中国证监会发布的《上市公司监管指引 公司募集资金管理和使用的 监管要求》和上海证券交易所发布的《 本易所利创板上市公司自律监管指引第 1 号 -- 规范运作》等有关规定,编制《董事会关于公司募集资金年度存放与实际使用情况的 专项报告》,提供真实、合法、完 ...

杭州安旭生物科技股份有限公司 审计报告 众环审字(2025) 0300320号 m 录 审计报告 | 财务报表 | | | --- | --- | | 合并资产负债表 | | | 合并利润表 | 61 | | 合并现金流量表 | ব | | 合并股东权益变动表 | 5 | | 资产负债表 | 7 | | 利润表 | 0 | | 现金流量表 | 10 | | 股东权益变动表 | 11 | | 财务报表附注 | 13 | | 财务报表附注补充资料 | | 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof 起始页码 审计报告 众环审字(2025) 0300320 号 杭州安旭生物科技股份有限公司全体股东: 一、审计意见 我们审计了杭州安旭生物科技股份有限公司(以下简称"安旭生物公司")财务报表, 包括 2024年 12月 31日的合并及公司资产负债表,2024年度的合并及公司利润表、合并及 公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 安旭生物公司 2024年12月 31 舟台并函公 ...

杭州安旭生物科技股份有限公司 内部控制审计报告 众环审字(2025) 0300321号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 报告编码: 鄂25A9274V4H 杭州安旭生物科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了杭 州安旭生物科技股份有限公司 (以下简称"安旭生物公司") 2024 年 12 月 31 日的财务报告 内部控制的有效性。 作 Tal. (197-867012 内部控制审计报告 众环审字(2025) 0300321 号 一、安旭生物公司对内部控制的责任 按照《企业内部控制基本规范》《企 制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部经制, 数性度安旭生物公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发惑审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部 ...

民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 2024年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票 上市规则》、《上海证券交易所上市公司持续督导工作指引》等有关法律、法 规的规定，民生证券股份有限公司（以下简称"民生证券"或"保荐机构"） 作为杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"） 持续督导工作的保荐机构，负责安旭生物上市后的持续督导工作，并出具本 持续督导年度跟踪报告。 一、持续督导工作情况 | 序号 | 工作情况 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 保荐机构已建立健全并有效执行了持续 | | 1 | 度，并针对具体的持续督导工作制定相 | | | | | 督导制度，并制定了相应的工作计划 | | | 应的工作计划 | | | | 根据中国证监会相关规定，在持续督导 | 保荐机构已与安旭生物签订《保荐协 | | | 工作开始前，与上市公司或相关当事人 | | | | | 议》，该协议明确了双方在持续督导期 | | 2 | 签署持续督导协议，明确双方在持续督 | ...

法律意见书 地址：浙江省杭州市上城区富春路 308 号华成国际发展大厦 11/12 层 电话：0571-89838088 传真：0571-89838099 邮编：310020 上海锦天城（杭州）律师事务所 关于杭州安旭生物科技股份有限公司 2024 年限制性股票激励计划部分限制性股票作废事项的 上海锦天城（杭州）律师事务所 法律意见书 上海锦天城（杭州）律师事务所 关于杭州安旭生物科技股份有限公司 2024 年限制性股票激励计划部分限制性股票作废事项的 法律意见书 上锦杭【2025】法意字第40427-1号 致：杭州安旭生物科技股份有限公司 上海锦天城（杭州）律师事务所（以下简称"锦天城"或"本所"）接受杭州 安旭生物科技股份有限公司（以下简称"公司"）的委托，担任公司 2024 年限制 性股票激励计划（以下简称"本次激励计划"）的专项法律顾问，根据《中华人民 共和◿公司法》（以下简称"《公司法》"）、《中华人民共和◿证券法》（以下 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《上海 证券交易所科创板上市公 ...

民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 开展远期结售汇及外汇衍生产品业务的核查意见 民生证券股份有限公司（以下简称"民生证券"、"保荐机构"）作为杭州安 旭生物科技股份有限公司（以下简称"安旭生物"、"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《中华人民共和国公司法》、《中华人民共和国 证券法》、《上市公司章程指引》、《证券发行上市保荐业务管理办法》、《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券易交 所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》、《科创板上市公司持续监管办法（试行）》等有关法律法规和规 范性文件的要求，民生证券对安旭生物开展远期结售汇及外汇衍生产品业务的事 项进行了审慎核查，核查情况如下： 一、办理远期结售汇及外汇衍生产品的目的 公司经营业务活动开展过程中存在境外销售和境外采购，结算币种主要采 用美元。为了有效规避外汇市场风险，防范汇率大幅波动对公司经营业绩造成的 不利影响，提高外汇资金使用效益，公司（包括境内外全资、控股子公司，下同） 计划与银行开展远期结售汇及外汇衍生产品等 ...